Recent Company News

• 09:20 AM ET Jul 10, 2025
  

  Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

• 08:00 AM ET Jul 09, 2025
  

  Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

• 08:01 AM ET Jun 11, 2025
  

  Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

• 08:01 AM ET Jun 05, 2025
  

  Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

• 06:08 PM ET Dec 05, 2023
  

  Kazia Therapeutics closes registered direct offering to raise $2M at $0.45/ADS through HC Wainwright

• 08:07 AM ET Dec 01, 2023
  

  Kazia Therapeutics announces $2M registered direct offering through HC Wainwright ($0.56, 0.00)

• 07:25 AM ET Nov 29, 2023
  

  Kazia Therapeutics signs LOI to grant rights for development, commercialization of paxalisib outside of oncology

• 07:11 PM ET Nov 14, 2023
  

  Kazia Therapeutics will be removed from the Official List at the close of trading today, 15-Nov (A$0.08, 0.00)